JP Morgan Chase
TGTX icon

JP Morgan Chase’s TG Therapeutics TGTX Stock Holding History

JP Morgan Chase’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.1M Buy
407,499
+256,976
+171% +$10.5M ﹤0.01% 2104
2026
Q1 		$4.74M Buy
150,523
+18,577
+14% +$554K ﹤0.01% 3360
2025
Q4 		$3.93M Sell
131,946
-95,988
-42% -$3.13M ﹤0.01% 3547
2025
Q3 		$8.23M Buy
227,934
+81,907
+56% +$2.7M ﹤0.01% 2896
2025
Q2 		$5.26M Sell
146,027
-441,977
-75% -$16.5M ﹤0.01% 3112
2025
Q1 		$23.2M Buy
588,004
+205,045
+54% +$6.9M ﹤0.01% 1802
2024
Q4 		$11.5M Sell
382,959
-337,839
-47% -$9.7M ﹤0.01% 2561
2024
Q3 		$16.9M Buy
720,798
+270,286
+60% +$5.9M ﹤0.01% 2140
2024
Q2 		$8.01M Buy
450,512
+85,837
+24% +$1.37M ﹤0.01% 2650
2024
Q1 		$5.55M Buy
364,675
+97,907
+37% +$1.56M ﹤0.01% 3014
2023
Q4 		$4.56M Buy
266,768
+62,218
+30% +$723K ﹤0.01% 3177
2023
Q3 		$1.71M Sell
204,550
-70,420
-26% -$982K ﹤0.01% 3663
2023
Q2 		$6.83M Sell
274,970
-129,778
-32% -$3.35M ﹤0.01% 2626
2023
Q1 		$6.09M Buy
404,748
+116,932
+41% +$1.78M ﹤0.01% 2664
2022
Q4 		$3.4M Sell
287,816
-942
-0.3% -$6.84K ﹤0.01% 3143
2022
Q3 		$1.71M Sell
288,758
-2,231
-0.8% -$14.6K ﹤0.01% 3603
2022
Q2 		$1.24M Buy
290,989
+22,535
+8% +$141K ﹤0.01% 3920
2022
Q1 		$2.55M Buy
268,454
+8,343
+3% +$96.6K ﹤0.01% 3562
2021
Q4 		$4.94M Buy
260,111
+99,635
+62% +$2.59M ﹤0.01% 3068
2021
Q3 		$5.34M Sell
160,476
-2,164
-1% -$67K ﹤0.01% 2979
2021
Q2 		$6.31M Sell
162,640
-12,683
-7% -$498K ﹤0.01% 2849
2021
Q1 		$8.45M Buy
175,323
+14,929
+9% +$717K ﹤0.01% 2521
2020
Q4 		$8.34M Sell
160,394
-16,225
-9% -$548K ﹤0.01% 2357
2020
Q3 		$4.62M Sell
176,619
-7,024
-4% -$162K ﹤0.01% 2637
2020
Q2 		$3.58M Sell
183,643
-20,929
-10% -$337K ﹤0.01% 2711
2020
Q1 		$2.01M Sell
204,572
-48,524
-19% -$613K ﹤0.01% 2961
2019
Q4 		$2.81M Sell
253,096
-19,992
-7% -$152K ﹤0.01% 3125
2019
Q3 		$1.53M Buy
273,088
+14,792
+6% +$103K ﹤0.01% 3577
2019
Q2 		$2.06M Sell
258,296
-11,702
-4% -$88.5K ﹤0.01% 3360
2019
Q1 		$2.17M Sell
269,998
-17,720
-6% -$95.8K ﹤0.01% 3270
2018
Q4 		$1.18M Sell
287,718
-16,779
-6% -$83.4K ﹤0.01% 3639
2018
Q3 		$1.71M Buy
304,497
+19,957
+7% +$228K ﹤0.01% 3567
2018
Q2 		$3.74M Sell
284,540
-15,697
-5% -$216K ﹤0.01% 2918
2018
Q1 		$4.26M Sell
300,237
-259,316
-46% -$3.31M ﹤0.01% 2711
2017
Q4 		$4.59M Buy
559,553
+201,928
+56% +$1.76M ﹤0.01% 2751
2017
Q3 		$4.22M Sell
357,625
-6,400
-2% -$72.9K ﹤0.01% 2679
2017
Q2 		$3.66M Buy
364,025
+111,155
+44% +$1.24M ﹤0.01% 2684
2017
Q1 		$2.95M Buy
252,870
+217,724
+619% +$1.56M ﹤0.01% 2799
2016
Q4 		$163K Buy
+35,146
New +$206K ﹤0.01% 4245
2016
Q3 		– Sell
-157
Closed -$1K – 4797
2016
Q2 		$1K Hold
157
– – ﹤0.01% 4690
2016
Q1 		$1K Buy
+157
New +$1.37K ﹤0.01% 4585
2015
Q1 		– Sell
-798,361
Closed -$12.6M – 4264
2014
Q4 		$12.6M Sell
798,361
-827,168
-51% -$10.8M ﹤0.01% 1783
2014
Q3 		$17.3M Sell
1,625,529
-648,247
-29% -$6.01M ﹤0.01% 1538
2014
Q2 		$21.4M Sell
2,273,776
-551,260
-20% -$3.52M 0.01% 1306
2014
Q1 		$19.5M Buy
+2,825,036
New +$16.7M 0.01% 1336
2013
Q3 		– Sell
-11,491
Closed -$73K – 4453
2013
Q2 		$73K Buy
+11,491
New +$73.6K ﹤0.01% 4217

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

JP Morgan Chase's TGTX Position: Q2 2026 in Review

JP Morgan Chase increased its TG Therapeutics (TGTX) stake by 171% in Q2 2026, buying an estimated $10.5M and bringing the position to 407,499 shares worth $23.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2104.

JP Morgan Chase first reported a position in TGTX in Q2 2013 and has held it in 46 quarters since. The position peaked at $23.2M in Q1 2025. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • JP Morgan Chase held 407,499 shares of TG Therapeutics worth $23.1M as of Q2 2026.
  • JP Morgan Chase bought 256,976 TG Therapeutics shares in Q2 2026, an estimated $10.5M.
  • TG Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2104 holding.
  • JP Morgan Chase first reported a position in TG Therapeutics in Q2 2013 and has held it in 46 quarters since.
  • JP Morgan Chase's TG Therapeutics position peaked at $23.2M in Q1 2025.
  • 428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.